CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

PartnershiplixudebartPositive

AI Analysis

Summary

CSL and Alentis Therapeutics entered into an exclusive global partnership to develop and commercialise lixudebart for rare kidney and liver diseases. Alentis will receive $355 million upfront and up to $1.2 billion in commercial milestones with global profits shared.

Importance:7/10

Sentiment:

0.70

partnershiplicensingrare diseasekidney diseaseliver diseasecommercialization

Related Companies

$GBCYD $BMGL

Read the original article

Published by PR Newswire Pharma on October 4, 2026 9:42 PM

Read Original